HIL-214 is a subunit vaccine commercialized by HilleVax, with a leading Phase III program in Gastroenteritis. According to Globaldata, it is involved in 12 clinical trials, of which 11 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of HIL-214’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for HIL-214 is expected to reach an annual total of $122 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
HIL-214 was under development for the prevention of acute gastroenteritis caused by norovirus. The vaccine candidate is administered through intramuscular route as a suspension. It is a norovirus GI.1/GII 4 bivalent virus-like particle (VLP) vaccine adjuvanted with monophosphoryl lipid A (MPL) and aluminum hydroxide (AlOH). MPL increases the vaccine’s immunogenic effect.
HilleVax is a biopharmaceutical company that develop vaccine to protect against norovirus infection. The company is headquartered in United States.
The operating loss of the company was US$53.4 million in FY2021, compared to an operating loss of US$1.3 million in FY2020. The net loss of the company was US$102.4 million in FY2021, compared to a net loss of US$2.1 million in FY2020.
For a complete picture of HIL-214’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.